Cysteine proteinase inhibitor cystatin A in breast cancer.

Cystatin A (acid cysteine proteinase inhibitor; ACPI) is a natural inhibitor of cysteine proteinases. It has been suggested that an inverse correlation exists between cystatin A and malignant progression. We wanted to assess the biological and clinical significance of cystatin A in infiltrative breast carcinoma by immunohistochemical staining. Formalin-fixed paraffin-embedded material from 440 cases treated during the years 1988-1991 was used in the study. After exclusion of patients with disseminated disease at diagnosis, previous contralateral breast carcinoma, and absence of follow-up data, 384 patients could be included in the survival analysis. For immunohistochemical analysis of cystatin A, we used monoclonal cystatin A antibody WR-23/2/3/3, the binding of which was detected by the avidin-biotin-peroxidase method. Immunohistochemical analysis of Bcl-2 and p53 was also done, and mitotic activity was evaluated. Positive staining for cystatin A was found in 52 of 440 cases. The staining was irregular but showed irrefutably positive areas within neoplastic tissue. Most of the positive tumors were of the ductal infiltrative type, but two were mucinous carcinomas, one medullary and one squamous cell carcinoma. No lobular carcinomas showed positive staining. Focal cystatin A positivity was seen in myoepithelial cells of benign ducts. Occasional apoptotic bodies within the neoplasm showed strong positivity for cystatin A. Tumors positive for cystatin A were of larger size and had higher mitotic activity than cystatin A-negative tumors. Cystatin A was associated with negative Bcl-2 staining, but there was no statistically significant association between axillary lymph node status or p53 immunostaining. The risk for breast cancer-related death was significantly higher in patients with cystatin A-positive tumors than in those with cystatin A-negative ones. The risk increase was significant also in lymph node-negative patients. After adjusting for the effect of tumor size, histological grade, and lymph node status, cystatin A-positive patients still had a higher risk of death. Patients with cystatin A and p53 coexpression had a higher risk of death than the other patients. The findings reveal a new variant of aggressive breast cancer. This type of carcinoma may develop during tumor progression through genetic instability that allows cystatin A expression and gives growth advantage to a clone of tumor cells.

[1]  M. Laato,et al.  Expression of acid cysteine proteinase inhibitor (acpi) in the normal human prostate, benign prostatic hyperplasia and adenocarcinoma , 1995, International journal of cancer.

[2]  D. Sarma,et al.  Hepatocarcinogenesis: a dynamic cellular perspective. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[3]  A. Rinne.  Epidermal SH-protease inhibitor in human neoplasms and their metastases. , 1980, Pathology, research and practice.

[4]  A. Rinne,et al.  A protein reminiscent of the epidermal SH-protease inhibitor occurs in squamous epithelia of man and rat. , 1978, Acta histochemica.

[5]  C. Tzeng,et al.  Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. , 1996, Anticancer research.

[6]  K. Wong,et al.  Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary glands. , 1994, European journal of biochemistry.

[7]  G. Gores,et al.  The role of proteases during apoptosis , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  L. Benítez-Bribiesca.  [Apoptosis in the pathogenesis and treatment of disease]. , 1995, Gaceta medica de Mexico.

[9]  Bonnie F. Sloane,et al.  Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. , 1989, Biochimica et biophysica acta.

[10]  W. Fiers,et al.  Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis , 1995, Nature.

[11]  S. Orrenius,et al.  Involvement of multiple proteases during Fas‐mediated apoptosis in T lymphocytes , 1995, FEBS letters.

[12]  R. Golouh,et al.  Stefins and lysosomal cathepsins B, L and D in human breast carcinoma , 1992, International journal of cancer.

[13]  A. Rinne,et al.  Identification of acid cysteine proteinase inhibitor (cystatin A) in the human thymus , 1994, The Anatomical record.

[14]  A. Barrett,et al.  Cystatin-like cysteine proteinase inhibitors from human liver. , 1984, The Biochemical journal.

[15]  D. Roop,et al.  Molecular cloning of mouse epidermal cystatin A and detection of regulated expression in differentiation and tumorigenesis , 1988, Molecular carcinogenesis.

[16]  Bonnie F. Sloane,et al.  Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. , 1995, Biological chemistry Hoppe-Seyler.

[17]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[18]  P. Calder,et al.  Inhibition of ICE‐family cysteine proteases rescues murine lymphocytes from lipoxygenase inhibitor‐induced apoptosis , 1996, FEBS Letters.

[19]  S. Nagata,et al.  Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.

[20]  P. V. van Diest,et al.  Standardized mitotic counts in breast cancer. Evaluation of the method. , 1996, Pathology, research and practice.

[21]  S. Nagata,et al.  Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis , 1996, Nature.

[22]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .

[23]  A. Rinne,et al.  Demonstration of immunoreactive acid cysteine-proteinase inhibitor in reticulum cells of lymph node germinal centres , 1983, Virchows Archiv. B, Cell pathology including molecular pathology.

[24]  H. Kirschke,et al.  Lysosomal cysteine proteinases. , 1998, Ciba Foundation symposium.

[25]  Y. Collan,et al.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. , 1989, Pathology, research and practice.

[26]  E. Alnemri,et al.  Inhibition of ICE-related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. , 1997, Experimental cell research.

[27]  A. Haeberli.  Human protein data , 1998 .

[28]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[29]  Shai Shaham,et al.  The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme , 1993, Cell.

[30]  R. Golouh,et al.  Cystatins and cathepsins in breast carcinoma. , 1992, Biological chemistry Hoppe-Seyler.

[31]  A. Rinne,et al.  Hodgkin's disease: a malignancy of follicular dendritic cells? , 1994, The Lancet.

[32]  A. Rinne,et al.  Immunolocalization of cystatin A in neoplastic, virus and inflammatory lesions of the uterine cervix. , 1992, Acta histochemica.

[33]  A. Rinne,et al.  Acid and neutral cysteine proteinase inhibitor in normal uterine portio and in squamo-epithelial metaplasia, dysplasias and infiltrative carcinoma of the uterine portio. , 1984, Experimental pathology.

[34]  A. Rinne,et al.  Behaviour of dendritic reticulum cells possessing immunoreactive acid cysteine‐proteinase inhibitor in human lymphoid secondary follicles and in follicular‐centre cell lymphomas , 1985, International journal of cancer.

[35]  Junying Yuan,et al.  Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.

[36]  J. Mankovich,et al.  Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. , 1995, Science.

[37]  A. Rinne,et al.  Rhabdovirus-induced apoptosis in a fish cell line is inhibited by a human endogenous acid cysteine proteinase inhibitor , 1997, Journal of virology.

[38]  V. Kosma,et al.  Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosis , 1995, The Journal of pathology.